IL37 and inflammatory bowel disease: IL-23 inhibitors, which target IL-23, a cytokine critical for the differentiation and survival of T helper 17 cells [32–34], offer a novel approach to modulate the immune response in IBD [17], potentially offering a more targeted and effective treatment option [17] (Fig. 1).